Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from 2022 to 2023. Although spending for certain GLP-1 RAs increased ...

ABSTRACT: The increasing use of glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide, for weight management has sparked interest in understanding their broader physiological ...

Popular medications for obesity and diabetes have been linked to an increased risk of hair loss, particularly for women. Researchers and doctors weigh in.

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk ...

Institute of Marine Biology and Pharmacology, Ocean College, Zhejiang University, Zhoushan 316021, China ...

Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new study says.

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

But insulin treatment for type 1 diabetes combined with today’s society have caused obesity rates to increase in those patients – and along with that, the use of GLP-1 drugs. GLP-1 drugs mimic the GLP ...

Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from ...

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...